Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultralow Dose 18F-FDG PET Imaging
NCT06956391Phase 2Recruiting
- Sponsor
- Akiva Mintz
- Start
- May 2025
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludeoxyglucose f 18 in cancer, sponsored by Akiva Mintz. Primary endpoints: Signal-to-Noise Ratio at Day 1, Contrast-to-Noise Ratio at Day 1 and 5 more. Started May 2025; status: recruiting.
02
Drugs
fludeoxyglucose f 18
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06956391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06956391.